Skip to main content
UniHealth

Doctor search

Silvina Pugliese, MD

Dermatology · Jamaica

NPI 1396057105

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
1
1 carrier
Offices
4

Offices

4 locations · New York University · 5,925 clinicians in this group

Looking this up.

Hospitals listed: NYU Langone Hospitals · Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

1 plan · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pugliese’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A118309 · Current

Licensed to practise in California · since 2011 · expires 2027-03-31 · Boston University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • NYU Langone HospitalsNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of NYU Langone Health, which runs 5 hospitalsHome of Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 75% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 11.9 (10.8 to 13.2) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.56 to 0.78), Jul 2022 – Jun 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 110.18 (84.1 to 136.26) · 561 cases, Jul 2022 – Jun 2024Better than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 2.66 (1.81 to 3.51) · 16,112 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 3.24 (1.36 to 5.12) · 9,218 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.56 (1.28 to 3.83) · 9,540 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.39, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.097, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.529, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.7 (3.1 to 4.4) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 10.5 (9.1 to 12.3) · 10,521 cases, Jan 2022 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.7 to 0.8) · 6,063 cases, Jan 2024 – Dec 2024
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for NYU Langone Hospitals

Behind the star rating — Deaths: 8 better, 0 the same, 0 worse of 8 measures. Safety: 5 better, 2 the same, 1 worse of 8 measures. Readmissions: 8 better, 1 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at NYU Langone Hospitals
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits11.9 (10.8 to 13.2) · 2,678 casesWorseJan 2024 – Dec 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.67 (0.56 to 0.78)BetterJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths110.18 (84.1 to 136.26) · 561 casesBetterJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.66 (1.81 to 3.51) · 16,112 casesBetterJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths3.24 (1.36 to 5.12) · 9,218 casesBetterJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths2.56 (1.28 to 3.83) · 9,540 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.291BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.39BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.097BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.529BetterOct 2024 – Sep 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits3.7 (3.1 to 4.4) · 2,678 casesBetterJan 2024 – Dec 2024
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits10.5 (9.1 to 12.3) · 10,521 casesBetterJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.7 to 0.8) · 6,063 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.48 (0.95 to 2.01) · 9,995 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 331 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths5.2 · 532 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths6.7 · 547 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths5.2 · 2,910 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths8 · 4,115 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths7.4 · 1,351 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths1.6 · 23,286 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0.01 to 0.24) · 48,461 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.23 (0.12 to 0.34) · 50,693 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.38 (0.66 to 2.11) · 9,390 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.79 (0.99 to 2.59) · 12,979 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.62 (0.53 to 2.72) · 3,510 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.6 (0.38 to 0.82) · 40,829 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths2.8 · 3,298 casesNoneApr 2023 – Mar 2025
SSI - Abdominal HysterectomyInfections1.091No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.859No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.3 · 667 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits18.7 · 4,060 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-23.8 · 603 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-22.8 · 3,334 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.5 · 4,338 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.4 · 5,069 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits3.7 · 3,383 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits6.8 · 386 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.7 · 820 casesNoneJul 2023 – Jun 2025

What patients said (10,034 patients answered, 23% of those asked)

Patient survey stars by topic at NYU Langone Hospitals
Cleanliness3
Nurse communication4
Doctor communication3
Communication about medicines3
Discharge information3
Overall hospital rating4
Quietness2
Recommend hospital4
Share of patients giving the best answer at NYU Langone Hospitals
Room was "always" clean70%
Nurses "always" communicated well80%
Doctors "always" communicated well79%
Staff "always" explained62%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge85%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully77%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)72%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night49%
"YES", patients would definitely recommend the hospital75%
Staff "always" explained possible side effects48%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$111,525

Medicare paid this office $111,525 for 680 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)175$23,042$88
Short return visit (20+ min)213$17,656$60
New patient visit (45+ min)76$9,202$121
Destruction of precancer skin growth, 1 growth114$7,155$46
Long return visit (40+ min)35$6,215$129
See all 19 services
Every Original Medicare service billed
Return visit (30+ min)175$23,042$88
Short return visit (20+ min)213$17,656$60
New patient visit (45+ min)76$9,202$121
Destruction of precancer skin growth, 1 growth114$7,155$46
Long return visit (40+ min)35$6,215$129
Destruction of skin growth, 1-14 growths75$5,884$67
New patient visit (30+ min)76$5,438$72
Biopsy of related skin growth, first growth134$4,454$26
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes137$4,062$29
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes24$2,971$102
New patient visit (60+ min)18$2,886$160
Destruction of precancer skin growth, 15 or more growths23$2,628$80
Biopsy of related skin growth, each additional growth65$2,326$19
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes19$2,213$116
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's102$1,752$15
Punch biopsy, first skin growth31$1,232$39
Destruction of precancer skin growth, 2-14 growths96$1,158$2
Punch biopsy, each additional skin growth22$571$22
Punch biopsy, first skin growth12$506$42

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions251More than 81% of doctors who do this
Skin biopsy229More than 87% of doctors who do this

Who their Medicare patients are

680 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 13% · Women 54% · Also on Medicaid 25% · Health risk score 2.20. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 69% · Chronic kidney disease 34% · Cancer 34% · Diabetes 28% · Coronary heart disease 25% · Atrial fibrillation 21% · Depression 19% · Heart failure 17% · COPD 14% · Dementia 9% · Stroke 9%.

The office billed $526,708, Medicare allowed $146,072 and paid $111,525; for 2,504 services of 38 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20246802,504732.20$526,708$111,525
20234801,996732.08$373,470$80,698
20223771,608731.74$264,198$61,089
2021251932721.84$198,160$43,823
2020202690722.15$123,776$24,603
20193061,331712.16$176,306$52,640
20183331,375712.13$152,201$48,757
20173931,433701.82$201,290$59,377
2016283928712.02$150,170$44,982
2015229859721.90$126,196$38,942
201496334711.23$39,912$16,563
201340128751.02$10,335$7,553

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 15 services

Original Medicare services billed in 2023
Return visit (30+ min)130$15,806$84
Short return visit (20+ min)144$11,424$55
Long return visit (40+ min)53$7,505$125
Destruction of precancer skin growth, 1 growth111$7,179$46
New patient visit (45+ min)57$6,643$117
Destruction of skin growth, 1-14 growths62$4,884$64
Biopsy of related skin growth, first growth117$3,575$24
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes111$3,550$31
New patient visit (30+ min)41$2,923$71
Destruction of precancer skin growth, 15 or more growths22$2,737$91
New patient visit (60+ min)14$2,300$164
Biopsy of related skin growth, each additional growth57$1,913$20
Punch biopsy, first skin growth31$1,328$38
Destruction of precancer skin growth, 2-14 growths99$1,214$2
Punch biopsy, each additional skin growth17$466$23

2022: 17 services

Original Medicare services billed in 2022
Return visit (30+ min)103$11,842$84
Short return visit (20+ min)150$11,134$54
New patient visit (45+ min)49$5,901$120
Destruction of precancer skin growth, 1 growth85$5,275$43
Destruction of skin growth, 1-14 growths52$3,816$61
New patient visit (30+ min)51$3,633$71
Long return visit (40+ min)22$3,334$123
Biopsy of related skin growth, first growth88$2,709$24
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes19$1,712$90
Biopsy of related skin growth, each additional growth46$1,592$19
Destruction of precancer skin growth, 15 or more growths15$1,471$92
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$1,122$94
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes16$973$61
Destruction of precancer skin growth, 2-14 growths75$965$2
Punch biopsy, first skin growth27$952$35
Punch biopsy, each additional skin growth20$533$23
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes11$355$32

2021: 15 services

Original Medicare services billed in 2021
Return visit (30+ min)89$10,640$85
Short return visit (20+ min)106$8,239$58
New patient visit (45+ min)37$4,449$120
Destruction of precancer skin growth, 1 growth51$2,594$47
New patient visit (30+ min)32$2,375$74
Destruction of skin growth, 1-14 growths24$2,150$65
Biopsy of related skin growth, first growth65$1,992$26
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$1,814$95
Long return visit (40+ min)11$1,552$119
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes17$1,461$66
Punch biopsy, first skin growth25$1,134$42
Biopsy of related skin growth, each additional growth32$873$19
Short return visit15$545$32
Destruction of precancer skin growth, 2-14 growths44$446$2
Punch biopsy, each additional skin growth15$379$24

2020: 14 services

Original Medicare services billed in 2020
Return visit (30+ min)65$4,636$60
Short return visit (20+ min)54$2,683$42
Return visit (30+ min)22$1,532$64
Long return visit (40+ min)12$1,337$103
Destruction of precancer skin growth, 1 growth31$1,260$36
Destruction of skin growth, 1-14 growths15$1,127$66
New patient visit (30+ min)17$900$53
Biopsy of related skin growth, first growth34$893$25
Short return visit (20+ min)16$845$47
New patient visit (15+ min)19$747$39
Destruction of precancer skin growth, 1 growth15$723$48
Biopsy of related skin growth, each additional growth15$359$20
Destruction of precancer skin growth, 2-14 growths27$268$2
Destruction of precancer skin growth, 2-14 growths11$98$2

2019: 24 services

Original Medicare services billed in 2019
Return visit (30+ min)69$6,915$71
Return visit (30+ min)59$4,729$67
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes27$4,151$94
Long return visit (40+ min)26$3,130$98
Short return visit (20+ min)55$3,011$44
New patient visit (45+ min)25$2,916$117
Destruction of precancer skin growth, 1 growth45$2,637$45
Short return visit (20+ min)39$2,368$46
Destruction of precancer skin growth, 1 growth30$2,200$48
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes25$2,112$66
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes20$1,794$90
Punch biopsy, first skin growth32$1,583$44
New patient visit (30+ min)23$1,577$69
Biopsy of related skin growth, first growth49$1,432$25
New patient visit (30+ min)23$1,357$59
Destruction of skin growth, 1-14 growths19$1,275$64
Destruction of skin growth, 1-14 growths17$1,227$68
Biopsy of related skin growth, first growth29$877$25
Biopsy of related skin growth, each additional growth14$619$21
Punch biopsy, each additional skin growth22$603$25
Biopsy of related skin growth, each additional growth15$526$19
Destruction of precancer skin growth, 2-14 growths39$522$2
Punch biopsy, first skin growth11$511$46
Destruction of precancer skin growth, 2-14 growths22$326$2

2018: 21 services

Original Medicare services billed in 2018
Return visit (30+ min)70$6,601$67
Return visit (30+ min)51$3,876$61
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$3,745$94
Short return visit (20+ min)71$3,738$41
Short return visit (20+ min)51$3,269$45
Destruction of precancer skin growth, 1 growth50$2,568$40
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes28$2,515$90
Long return visit (40+ min)20$2,514$97
Biopsy of single growth of skin and/or tissue59$2,371$34
Destruction of precancer skin growth, 1 growth35$2,363$46
Biopsy of single growth of skin and/or tissue59$1,948$29
New patient visit (30+ min)32$1,775$55
Destruction of skin growth, 1-14 growths23$1,561$56
New patient visit (45+ min)13$1,499$115
Destruction of skin growth, 1-14 growths18$1,372$62
New patient visit (30+ min)19$1,291$68
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes13$981$65
Biopsy of each additional growth of skin and/or tissue29$871$22
Destruction of precancer skin growth, 2-14 growths44$450$2
Biopsy of each additional growth of skin and/or tissue14$450$20
Destruction of precancer skin growth, 2-14 growths26$429$2

2017: 19 services

Original Medicare services billed in 2017
Return visit (30+ min)88$8,828$68
Return visit (30+ min)97$7,529$63
New patient visit (45+ min)45$5,137$114
Long return visit (40+ min)42$4,882$100
New patient visit (30+ min)67$4,198$63
Short return visit (20+ min)52$3,581$45
Destruction of skin growth, 1-14 growths39$3,264$62
Destruction of precancer skin growth, 1 growth54$2,858$45
Short return visit (20+ min)55$2,765$43
Biopsy of single growth of skin and/or tissue59$2,515$38
Biopsy of single growth of skin and/or tissue64$2,190$30
Destruction of precancer skin growth, 1 growth26$1,304$40
New patient visit (30+ min)19$1,290$68
Destruction of skin growth, 1-14 growths14$1,094$68
Biopsy of each additional growth of skin and/or tissue35$909$22
Biopsy of each additional growth of skin and/or tissue25$556$19
Destruction of precancer skin growth, 2-14 growths45$518$2
Destruction of precancer skin growth, 2-14 growths21$297$2
Short return visit13$226$17

2016: 19 services

Original Medicare services billed in 2016
Return visit (30+ min)93$7,887$66
Return visit (30+ min)80$7,826$68
New patient visit (45+ min)51$5,728$112
Long return visit (40+ min)24$2,999$97
New patient visit (30+ min)41$2,470$60
Biopsy of single growth of skin and/or tissue56$2,147$35
New patient visit (45+ min)20$2,011$101
Destruction of precancer skin growth, 1 growth42$1,928$44
Biopsy of single growth of skin and/or tissue45$1,833$38
Destruction of precancer skin growth, 1 growth28$1,418$46
Destruction of skin growth, 1-14 growths17$1,234$62
Long return visit (40+ min)11$1,189$99
New patient visit (30+ min)12$814$68
Destruction of skin growth, 1-14 growths11$748$62
Biopsy of each additional growth of skin and/or tissue26$657$23
Short return visit (20+ min)13$638$46
Biopsy of each additional growth of skin and/or tissue18$499$23
Destruction of precancer skin growth, 2-14 growths28$288$2
Destruction of precancer skin growth, 2-14 growths19$149$2

2015: 10 services

Original Medicare services billed in 2015
Return visit (30+ min)95$9,693$70
New patient visit (45+ min)55$6,319$115
New patient visit (30+ min)71$4,688$66
Biopsy of single growth of skin and/or tissue81$3,480$38
Short return visit (20+ min)53$3,068$45
Destruction of precancer skin growth, 1 growth50$2,623$45
Long return visit (40+ min)18$2,089$99
Destruction of skin growth, 1-14 growths23$1,836$68
Biopsy of each additional growth of skin and/or tissue38$1,018$23
Destruction of precancer skin growth, 2-14 growths37$446$2

2014: 5 services

Original Medicare services billed in 2014
New patient visit (30+ min)27$1,823$68
Short return visit (20+ min)25$1,731$49
Biopsy of single growth of skin and/or tissue17$1,306$77
Short return visit (20+ min)16$1,228$45
Biopsy of single growth of skin and/or tissue24$898$37

2013: 4 services

Original Medicare services billed in 2013
Biopsy of single growth of skin and/or tissue18$1,622$85
Short return visit (20+ min)24$1,573$58
New patient visit (30+ min)17$1,434$84
Destruction of precancer skin growth, 1 growth11$515$47

Medicaid work

$1,773 in 2024

Medicaid paid $1,773 for 29 billed services this clinician did in 2024, up to 17 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)17$1,264
Short return visit (20+ min)12$510
Medicaid work by year
202429217$1,773
202371215$2,552
202242215$1,842
202037222$1,096
201912112$424
2018147326$5,484
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)42$1,747
Short return visit (20+ min)29$805

2022

Largest Medicaid services in 2022
Return visit (30+ min)29$1,663
Short return visit (20+ min)13$178

2020

Largest Medicaid services in 2020
Short return visit (20+ min)24$612
Return visit (30+ min)13$484

2019

Largest Medicaid services in 2019
Return visit (30+ min)12$424

2018

Largest Medicaid services in 2018
Short return visit (20+ min)97$3,188
Return visit (30+ min)38$1,449
OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES12$847

Drugs they prescribed that Part D paid

$447,096

Pharmacies billed $447,096 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 1,054) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

990 generic and 64 brand-name prescriptions · $447,096 in drug cost · 35 antibiotic prescriptions to 29 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Taltz14$99,241$7,089
Cosentyx Sensoready (2 Pens)12$83,117$6,926
Fluorouracil56$3,603$64
Calcipotriene11$3,439$313
Clobetasol Propionate46$3,134$68
See all 31 drugs
Every Part D drug this clinician prescribed
Taltz14$99,241$7,089
Cosentyx Sensoready (2 Pens)12$83,117$6,926
Fluorouracil56$3,603$64
Calcipotriene11$3,439$313
Clobetasol Propionate46$3,134$68
Ketoconazole113$2,337$21
Tacrolimus25$2,248$90
Triamcinolone Acetonide106$1,497$14
Tretinoin18$1,488$83
Desonide26$1,182$45
Clindamycin Phosphate24$915$38
Ciclopirox26$867$33
Fluocinolone Acetonide15$775$52
Fluocinolone Acetonide14$753$54
Clindamycin-Benzoyl Peroxide16$716$45
Minoxidil64$642$10
Gentamicin Sulfate14$637$46
Metronidazole13$532$41
Hydroxyzine23$526$23
Ciclopirox44$500$11
Valacyclovir12$411$34
Mupirocin63$408$6
Hydroxychloroquine Sulfate16$401$25
Doxepin12$365$30
Fluocinonide17$330$19
Hydrocortisone52$318$6
Doxycycline Hyclate20$309$15
Nystatin13$291$22
Gabapentin24$170$7
Prednisone16$120$8
Terbinafine11$46$4

Year by year

Part D prescribing by year
20241,0542820% (0)6%$447,096
2023843231None9%$504,412
2022647170None9%$321,351
20214141130% (0)16%$268,203
20203761130% (0)9%$154,318
20194431500% (0)8%$74,781
20185301680% (0)12%$94,077
20175431890% (0)10%$70,455
2016420143None14%$28,396
2015293116None15%$38,047
20142811050% (0)None$60,568
2013178900% (0)None$48,057

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 20 drugs

Part D drugs prescribed in 2023
Taltz13$87,764$6,751
Calcipotriene25$27,556$1,102
Fluorouracil51$4,832$95
Tacrolimus25$3,422$137
Ketoconazole125$2,729$22
Clobetasol Propionate43$2,456$57
Metronidazole25$1,800$72
Ciclopirox30$1,389$46
Desonide27$1,254$46
Triamcinolone Acetonide70$1,236$18
Fluocinonide25$1,155$46
Doxycycline Hyclate26$844$32
Hydroxychloroquine Sulfate14$613$44
Mupirocin34$376$11
Clindamycin Phosphate11$306$28
Valacyclovir11$294$27
Minoxidil56$281$5
Hydrocortisone26$190$7
Ciclopirox17$189$11
Finasteride12$87$7

2022: 19 drugs

Part D drugs prescribed in 2022
Taltz14$89,048$6,361
Cosentyx Pen (2 Pens)11$75,352$6,850
Calcipotriene15$5,785$386
Fluorouracil41$4,604$112
Clobetasol Propionate21$2,040$97
Ketoconazole97$2,020$21
Tacrolimus14$1,660$119
Triamcinolone Acetonide75$1,481$20
Tretinoin11$1,363$124
Ciclopirox29$1,247$43
Hydroxychloroquine Sulfate17$1,218$72
Fluocinonide21$1,106$53
Fluocinolone Acetonide19$801$42
Doxycycline Hyclate17$595$35
Valacyclovir12$310$26
Minoxidil31$193$6
Hydrocortisone32$175$5
Mupirocin18$170$9
Finasteride16$108$7

2021: 16 drugs

Part D drugs prescribed in 2021
Taltz13$76,616$5,894
Cosentyx Pen (2 Pens)11$68,484$6,226
Otezla13$44,803$3,446
Tretinoin11$1,754$159
Fluorouracil20$1,719$86
Ketoconazole57$1,466$26
Triamcinolone Acetonide43$1,440$33
Clobetasol Propionate13$1,120$86
Doxycycline Hyclate24$933$39
Fluocinonide11$705$64
Tacrolimus11$663$60
Ciclopirox16$562$35
Fluocinolone Acetonide15$461$31
Ciclopirox12$228$19
Hydrocortisone26$167$6
Mupirocin20$151$8

2020: 12 drugs

Part D drugs prescribed in 2020
Taltz13$69,130$5,318
Fluocinonide27$2,285$85
Triamcinolone Acetonide54$1,500$28
Fluorouracil12$1,386$116
Ketoconazole48$938$20
Doxycycline Hyclate25$867$35
Clobetasol Propionate14$842$60
Ciclopirox17$507$30
Gabapentin21$248$12
Hydroxyzine11$183$17
Mupirocin14$142$10
Hydrocortisone19$119$6

2019: 13 drugs

Part D drugs prescribed in 2019
Fluocinonide24$1,857$77
Doxycycline Hyclate32$1,416$44
Clobetasol Propionate21$1,392$66
Valacyclovir17$1,312$77
Tacrolimus13$1,222$94
Triamcinolone Acetonide54$1,207$22
Ketoconazole62$1,076$17
Alclometasone Dipropionate13$686$53
Clindamycin Phosphate13$578$44
Ciclopirox13$577$44
Hydroxyzine15$343$23
Hydrocortisone33$193$6
Mupirocin12$135$11

2018: 12 drugs

Part D drugs prescribed in 2018
Clobetasol Propionate21$3,431$163
Fluorouracil24$2,491$104
Fluocinonide26$2,249$87
Triamcinolone Acetonide78$1,874$24
Ketoconazole68$1,572$23
Valacyclovir18$1,345$75
Alclometasone Dipropionate19$855$45
Ciclopirox23$655$28
Doxycycline Hyclate15$499$33
Hydroxyzine19$461$24
Hydrocortisone41$248$6
Mupirocin20$204$10

2017: 14 drugs

Part D drugs prescribed in 2017
Desoximetasone18$5,083$282
Fluorouracil22$2,899$132
Fluocinonide31$2,406$78
Clobetasol Propionate15$2,371$158
Ketoconazole70$2,132$30
Triamcinolone Acetonide83$1,497$18
Doxycycline Hyclate18$1,421$79
Alclometasone Dipropionate26$1,263$49
Ciclopirox26$946$36
Hydroxyzine26$378$15
Hydrocortisone36$214$6
Gabapentin12$165$14
Cephalexin17$160$9
Mupirocin17$112$7

2016: 10 drugs

Part D drugs prescribed in 2016
Clobetasol Propionate20$4,613$231
Fluocinonide39$2,783$71
Ketoconazole88$2,239$25
Fluorouracil13$2,028$156
Desonide18$1,359$76
Triamcinolone Acetonide62$989$16
Clindamycin Phosphate11$855$78
Mupirocin28$246$9
Hydroxyzine12$91$8
Hydrocortisone11$67$6

2015: 7 drugs

Part D drugs prescribed in 2015
Clobetasol Propionate22$4,034$183
Fluocinonide30$2,193$73
Desonide16$1,230$77
Ketoconazole41$1,106$27
Triamcinolone Acetonide40$650$16
Mupirocin15$149$10
Gabapentin11$91$8

2014: 8 drugs

Part D drugs prescribed in 2014
Enbrel12$31,815$2,651
Fluorouracil28$5,010$179
Clobetasol Propionate19$3,650$192
Fluocinolone Acetonide15$2,656$177
Fluocinolone Acetonide15$2,518$168
Ketoconazole55$987$18
Fluocinonide13$697$54
Triamcinolone Acetonide23$327$14

2013: 4 drugs

Part D drugs prescribed in 2013
Enbrel11$26,022$2,366
Fluorouracil21$3,978$189
Fluocinolone Acetonide18$1,847$103
Ketoconazole39$772$20

Money from drug and device companies

$7,552 in 2025

Industry payments by year
202527$7,096$7,552
202412None$348
202311None$15
202211None$72

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Regeneron PharmaceuticalsLibtayo$7,417
6 payments
  • Consulting for Libtayo · 2025-12-05 · $887
  • Consulting for Libtayo · 2025-12-05 · $4,435
  • Consulting for Libtayo · 2025-12-05 · $1,774
  • Meals for Libtayo · 2025-11-13 · $144
  • Meals for Libtayo · 2025-11-13 · $36
  • Meals for Libtayo · 2025-11-13 · $141
Janssen BiotechTremfya$136
1 payment
  • Meals for Tremfya · 2025-04-25 · $136
See all 7 published payments
Every published payment
Regeneron PharmaceuticalsConsulting · 2025-12-05Libtayo$887
Regeneron PharmaceuticalsConsulting · 2025-12-05Libtayo$4,435
Regeneron PharmaceuticalsConsulting · 2025-12-05Libtayo$1,774
Regeneron PharmaceuticalsMeals · 2025-11-13Libtayo$144
Regeneron PharmaceuticalsMeals · 2025-11-13Libtayo$36
Regeneron PharmaceuticalsMeals · 2025-11-13Libtayo$141
Janssen BiotechMeals · 2025-04-25Tremfya$136
See earlier years (2024, 2023, 2022)

2024: $348

Payments by company in 2024
AbbvieSkyrizi$348
2 payments
  • Meals · 2024-06-26 · $236
  • Meals for Skyrizi · 2024-05-04 · $112

2023: $15

Payments by company in 2023
PfizerCibinqo$15
1 payment
  • Education for Cibinqo · 2023-05-12 · $15

2022: $72

Payments by company in 2022
PfizerCibinqo$72
1 payment
  • Meals for Cibinqo · 2022-04-29 · $72

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1396057105
Licence
CA A118309California A118309: Current · expires 2027-03-31
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
900 Blake Wilbur Dr, W1006, Palo Alto, CA, 94304
NPI first listed
2010-07-09
NPI last updated
2024-04-16
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 900 Blake Wilbur Dr, Palo Alto, CA, 94304